Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CML and the WHO: Why?
Berman E, Shah NP, Deninger M, Altman JK, Amaya M, Begna K, Bhatia R, Chan O, Collins R, Curtin P, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore J, Oehler V, Pratz K, Pusic I, Rose M, Shomali W, Smith BD, Styler M, Sweet K, Talpaz M, Tanaka T, Tantravahi S, Tsai S, Vaughn J, Welborn J, Yang D, Mauro M, Cortes J, Radich J, Druker B. Berman E, et al. Among authors: pusic i. J Clin Oncol. 2024 Mar 20;42(9):984-986. doi: 10.1200/JCO.23.01689. Epub 2023 Dec 12. J Clin Oncol. 2024. PMID: 38086008 No abstract available.
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, Chan O, Clements J, Collins RH, Curtin PT, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore JO, Oehler V, Pratz K, Pusic I, Rose MG, Shomali W, Smith BD, Styler M, Talpaz M, Tanaka TN, Tantravahi S, Thompson J, Tsai S, Vaughn J, Welborn J, Yang DT, Sundar H, Gregory K. Shah NP, et al. Among authors: pusic i. J Natl Compr Canc Netw. 2024 Feb;22(1):43-69. doi: 10.6004/jnccn.2024.0007. J Natl Compr Canc Netw. 2024. PMID: 38394770
Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease.
Wolff D, Cutler C, Lee SJ, Pusic I, Bittencourt H, White J, Hamadani M, Arai S, Salhotra A, Perez-Simon JA, Alousi A, Choe H, Kwon M, Bermúdez A, Kim I, Socié G, Chhabra S, Radojcic V, O'Toole T, Tian C, Ordentlich P, DeFilipp Z, Kitko CL; AGAVE-201 Investigators. Wolff D, et al. Among authors: pusic i. N Engl J Med. 2024 Sep 19;391(11):1002-1014. doi: 10.1056/NEJMoa2401537. N Engl J Med. 2024. PMID: 39292927 Clinical Trial.
Ibrutinib for therapy of steroid-refractory chronic graft vs. host disease: A multicenter real-world analysis.
Pidala JA, Kim J, Kalos D, Cutler CS, DeFilipp Z, Flowers ME, Hamilton BK, Chin KK, Rotta M, El Jurdi N, Hamadani M, Ahmed G, Kitko CL, Ponce DM, Sung AD, Tang H, Farhadfar N, Nemecek ER, Pusic I, Qayed M, Rangarajan HG, Hogan WJ, Etra AM, Jaglowski SM. Pidala JA, et al. Among authors: pusic i. Blood Adv. 2024 Oct 25:bloodadvances.2024014374. doi: 10.1182/bloodadvances.2024014374. Online ahead of print. Blood Adv. 2024. PMID: 39454280
Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: An Interventional Trial.
Dehn JG, Logan B, Shaw BE, Devine S, Ciurea SO, Horowitz M, He N, Pusic I, Srour SA, Arai S, Juckett M, Uberti J, Hill L, Vasu S, Hogan WJ, Hayes-Lattin B, Westervelt P, Bashey A, Farhadfar N, Grunwald MR, Leifer E, Symons H, Saad A, Vogel J, Erickson C, Buck K, Lee SJ, Pidala J. Dehn JG, et al. Among authors: pusic i. medRxiv [Preprint]. 2024 Sep 16:2024.09.16.24313494. doi: 10.1101/2024.09.16.24313494. medRxiv. 2024. PMID: 39371123 Free PMC article. Preprint.
Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response.
Jacoby MA, Duncavage ED, Khanna A, Chang GS, Nonavinkere Srivatsan S, Miller CA, Gao F, Robinson J, Shao J, Fulton RS, Fronick CC, O'Laughlin M, Heath SE, Brendel K, Chavez M, DiPersio JF, Abboud CN, Stockerl-Goldstein K, Westervelt P, Cashen A, Pusic I, Oh ST, Welch JS, Wells DA, Loken MR, Uy GL, Walter MJ. Jacoby MA, et al. Among authors: pusic i. Leukemia. 2024 Oct 4. doi: 10.1038/s41375-024-02426-0. Online ahead of print. Leukemia. 2024. PMID: 39367170
Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002.
Meyers G, Hamadani M, Martens M, Ali H, Chevallier P, Choe H, Harris AC, Holler E, van Hooren E, Klaassen W, Leifer E, van Oosterhout Y, Perez L, Pusic I, Stelljes M, van der Velden W, Ammatuna E, Beauvais D, Cornillon J, Maziarz RT, Schetelig J, Romeril J, MacMillan ML, Levine JE, Socié G. Meyers G, et al. Among authors: pusic i. Bone Marrow Transplant. 2023 Dec;58(12):1416-1418. doi: 10.1038/s41409-023-02110-4. Epub 2023 Sep 25. Bone Marrow Transplant. 2023. PMID: 37749187 No abstract available.
Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell Transplantation.
Xu Z, Choi J, Cooper M, King J, Fiala MA, Liu J, Pusic I, Romee R, Cashen A, Jacoby MA, Stockerl-Goldstein K, Abboud C, Vij R, Uy G, Westervelt P, Walter MJ, DiPersio JF, Schroeder MA. Xu Z, et al. Among authors: pusic i. Transplant Cell Ther. 2023 Nov;29(11):699.e1-699.e9. doi: 10.1016/j.jtct.2023.08.017. Epub 2023 Aug 17. Transplant Cell Ther. 2023. PMID: 37597685 Free article. Clinical Trial.
86 results